Biotech Values

[DewDiligence]

The premise is that good companies don’t need to employ inventive language in order to impress investors.

As red flags go, use of inventive language is relatively weak but surprisingly trustworthy. If it were a clinical trial, the clinical benefit would be modest but the p-value would be strong :- )